Post-SARS-CoV-2 Acute Telogen Effluvium: An Expected Complication
Abstract
:1. Introduction
2. Materials and Methods
2.1. Alopecia Assessment
2.2. Clinical Covariate Assessment
2.3. Laboratory
2.4. Statistics
3. Results
3.1. Characteristics of Participants
3.2. Post-COVID Alopecia Characteristics
3.3. COVID-19 Characteristics and Alopecia
3.4. Laboratory and Alopecia
4. Discussion
Author Contributions
Funding
Conflicts of Interest
References
- Malik, Y.S.; Sircar, S.; Bhat, S.; Vinodhkumar, O.R.; Tiwari, R.; Sah, R.; Rabaan, A.A.; Rodriguez-Morales, A.J.; Dhama, K. Emerging coronavirus disease (COVID-19), a pandemic public health emergency with animal linkages: Current status update. Preprints 2020, 2020030343. [Google Scholar] [CrossRef]
- COVID-19 Coronavirus Pandemic, 10 June. Worldometers.Info. Available online: https://www.worldometers.info/coronavirus/?utm_campaign=homeAdvegas1 (accessed on 18 August 2020).
- Li, L.; Li, R.; Wu, Z.; Yang, X.; Zhao, M.; Liu, J.; Chen, D. Therapeutic strategies for critically ill patients with COVID-19. Ann. Intensive Care 2020, 10, 45. [Google Scholar] [CrossRef] [PubMed]
- Wu, C.; Chen, X.; Cai, Y.; Xia, J.; Zhou, X.; Xu, S.; Huang, H.; Zhang, L.; Zhou, X.; Du, C.; et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern. Med. 2020, 180, 934–943. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wu, J.T.; Leung, K.; Leung, G.M. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: A modelling study. Lancet 2020, 395, 689–697. [Google Scholar] [CrossRef] [Green Version]
- McGonagle, D.; Sharif, K.; O’Regan, A.; Bridgewood, C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun. Rev. 2020, 19, 102537. [Google Scholar] [CrossRef]
- Zhao, Y.; Zhang, Y.-H.; Denney, L.; Young, D.; Powell, T.J.; Peng, Y.-C.; Li, N.; Yan, H.-P.; Wang, D.-Y.; Shu, Y.-L.; et al. High Levels of Virus-Specific CD4+T Cells Predict Severe Pandemic Influenza A Virus Infection. Am. J. Respir. Crit. Care Med. 2012, 186, 1292–1297. [Google Scholar] [CrossRef] [PubMed]
- Stewart, I.J.; Sosnov, J.A.; Howard, J.T.; Orman, J.A.; Fang, R.; Morrow, B.D.; Zonies, D.H.; Bollinger, M.; Tuman, C.; Freedman, B.A.; et al. Retrospective Analysis of Long-Term Outcomes after Combat Injury: A Hidden Cost of War. Circulation 2015, 132, 2126–2133. [Google Scholar] [CrossRef] [PubMed]
- Grover, C.; Khurana, A. Telogen effluvium. Indian J. Dermatol. Venereol. Leprol. 2013, 79, 591–603. [Google Scholar] [CrossRef] [PubMed]
- Headington, J.T. Telogen effluvium. New concepts and review. Arch Dermatol. 1993, 129, 356–363. [Google Scholar] [CrossRef] [PubMed]
- Rebora, A. Proposing a Simpler Classification of Telogen Effluvium. Skin Appendage Disord. 2016, 2, 35–38. [Google Scholar] [CrossRef] [Green Version]
- Shrivastava, S.B. Diffuse hair loss in an adult female: Approach to diagnosis and management. Indian J Dermatol Venereol Leprol. 2009, 75, 20–27, quiz 27–8. [Google Scholar] [CrossRef] [PubMed]
- Rudnicka, L.; Olszewska, M.; Rakowska, A.; Slowinska, M. Trichoscopy update 2011. J. Dermatol. Case Rep. 2011, 5, 82–88. [Google Scholar] [CrossRef] [PubMed]
- Ross, E.K.; Vincenzi, C.; Tosti, A. Videodermoscopy in the evaluation of hair and scalp disorders. J. Am. Acad. Dermatol. 2006, 55, 799–806. [Google Scholar] [CrossRef] [PubMed]
- Lacarrubba, F.; Dall’Oglio, F.; Nasca, M.R.; Micali, G. Videodermatoscopy enhances diagnostic capability in some forms of hair loss. Am. J. Clin. Dermatol. 2004, 5, 205–208. [Google Scholar] [CrossRef] [PubMed]
- Rakowska, A.; Olszewska, M.; Rudnicka, L. Telogen effluvium. In Atlas of Trichoscopy; Rudnicka, L., Olszewska, M., Rakowska, A., Eds.; Springer: London, UK, 2012; pp. 237–244. [Google Scholar]
- Olds, H.; Liu, J.; Luk, K.; Lim, H.W.; Ozog, D.; Rambhatla, P.V. Telogen effluvium associated with COVID-19 infection. Dermatol. Ther. 2021, 6, e14761. [Google Scholar] [CrossRef]
- Olsen, E.A.; Rosen, S.T.; Vollmer, R.T.; Variakojis, D.; Roenigk, H.H., Jr.; Diab, N.; Zeffren, J. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J. Am. Acad. Dermatol. 1989, 20, 395–407. [Google Scholar] [CrossRef]
- Watras, M.M.; Patel, J.P.; Arya, R. Traditional anticoagulants and hair loss: A role for direct oral anticoagulants? A review of the literature. Drugs Real World Outcomes 2016, 3, 1–6. [Google Scholar] [CrossRef] [Green Version]
- Cline, A.; Kazemi, A.; Moy, J.; Safai, B.; Marmon, S. A Surge in the Incidence of Telogen Effluvium in Minority Predominant Communities Heavily Impacted by COVID-19. J. Am. Acad. Dermatol. 2020, 84, 773–775. [Google Scholar] [CrossRef]
- Puntmann, V.O.; Carerj, M.L.; Wieters, I.; Fahim, M.; Arendt, C.; Hoffmann, J.; Shchendrygina, A.; Escher, F.; Vasa-Nicotera, M.; Zeiher, A.M.; et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020, 5, 1265–1273. [Google Scholar] [CrossRef]
- Wei, K.C.; Huang, M.S.; Chang, T.H. Dengue Virus Infects Primary Human Hair Follicle Dermal Papilla Cells. Front. Cell Infect. Microbiol. 2018, 8, 268. [Google Scholar] [CrossRef] [Green Version]
- Almagro, M.; del Pozo, J.; Garcia-Silva, J.; Castro, A.; López-Calvo, S.; Yebra-Pimentel, M.T.; Fonseca, E. Telogen effluvium as a clinical presentation of human immunodeficiency virus infection. Am. J. Med. 2002, 112, 508–509. [Google Scholar] [CrossRef]
- Gebhard, C.; Regitz-Zagrosek, V.; Neuhauser, H.K.; Morgan, R.; Klein, S.L. Impact of sex and gender on COVID-19 outcomes in Europe. Biol. Sex Differ. 2020, 11, 29. [Google Scholar] [CrossRef] [PubMed]
- Wambier, C.G.; Vaño-Galván, S.; McCoy, J.; Gomez-Zubiaur, A.; Herrera, S.; Hermosa-Gelbard, Á.; Moreno-Arrones, O.M.; Jiménez-Gómez, N.; González-Cantero, A.; Fonda-Pascual, P. Segurado-Miravalles, G. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign”. J. Am. Acad. Dermatol. 2020, 83, 680–682. [Google Scholar] [CrossRef] [PubMed]
- Montopoli, M.; Zumerle, S.; Vettor, R.; Rugge, M.; Zorzi, M.; Catapano, C.V.; Carbone, G.M.; Cavalli, A.; Pagano, F.; Ragazzi, E.; et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: A population-based study (N = 4532). Ann. Oncol. 2020, 31, 1040–1045. [Google Scholar] [CrossRef]
- Asghar, F.; Shamim, N.; Farooque, U.; Sheikh, H.; Aqeel, R. Telogen Effluvium: A Review of the Literature. Cureus 2020, 12, e8320. [Google Scholar] [CrossRef]
- Tosti, A.; Pazzaglia, M. Drug reactions affecting hair: Diagnosis. Dermatol. Clin. 2007, 25, 223–231. [Google Scholar] [CrossRef]
- Harrison, S.; Bergfeld, W. Diffuse hair loss: Its triggers and management. Cleve Clin. J. Med. 2009, 76, 361–367. [Google Scholar] [CrossRef]
- Sulzberger, M.B.; Witten, V.H.; Kopf, A.W. Diffuse alopecia in women. Its unexplained apparent increase in incidence. Arch Dermatol. 1960, 81, 556–560. [Google Scholar] [CrossRef]
Variable | OVERALLN = 96 | No-Alopecia n = 66 | Alopecia n = 30 | p-Value |
---|---|---|---|---|
Gender: | <0.001 | |||
F | 34 (35.4%) | 12 (18.2%) | 22 (73.3%) | |
M | 62 (64.6%) | 54 (81.8%) | 8 (26.7%) | |
Age (years) | 59.0 (54.5-65.0) | 59.0 (55.2;64.8) | 59.0 (53.2;66.5) | 0.880 |
Swab positivity(days) | 31.0 (26.0-37.0) | 31.0 (26.0;37.0) | 29.5 (25.2;34.5) | 0.274 |
Hospitalization (days) | 13.0 (9.0-16.5) | 14.0 (8.25;17.0) | 11.5 (10.0;15.0) | 0.444 |
Fever (days) | 11.0 (9.0-13.0) | 10.5 (8.25;13.0) | 11.0 (9.25;14.8) | 0.225 |
DRUG | ||||
Lopinavir: | 0.611 | |||
No | 72 (75.0%) | 48 (72.7%) | 24 (80.0%) | |
Yes | 24 (25.0%) | 18 (27.3%) | 6 (20.0%) | |
Darunavir: | 0.330 | |||
No | 12 (12.5%) | 10 (15.2%) | 2 (6.67%) | |
Yes | 84 (87.5%) | 56 (84.8%) | 28 (93.3%) | |
Ritonavir: | 0.847 | |||
No | 2 (2.1%) | 2 (3.03%) | 0 (0.00%) | |
Yes | 94 (97.9%) | 64 (97.0%) | 30 (100%) | |
Chloroquine: | 0.778 | |||
No | 13 (13.5%) | 9 (13.6%) | 4 (13.3%) | |
Yes | 83 (86.5%) | 57 (86.4%) | 26 (86.7%) | |
Azithromycine: | 0.977 | |||
No | 37 (38.5%) | 25 (37.9 | 12 (40.0%) | |
Yes | 59 (61.5%) | 41 (62.1%) | 18 (60.0%) | |
O2: | 0.233 | |||
No | 23 (24.0%) | 13 (19.7%) | 10 (33.3%) | |
Yes | 73 (76.0%) | 53 (80.3%) | 20 (66.7%) | |
Steroids: | 0.611 | |||
No | 72 (75.0%) | 48 (72.7%) | 24 (80.0%) | |
Yes | 24 (25.0%) | 18 (27.3%) | 6 (20.0%) | |
Pulmonary Embolism prophylaxis: | 0.049 | |||
No | 65 (67.7%) | 40 (60.6%) | 25 (83.3%) | |
Yes | 31 (32.3%) | 26 (39.4%) | 5 (16.7%) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Monari, P.; Gualdi, G.; Bettoni, G.; Costa, R.; Ragni, G.; Zani, F.; Bianchi, G.; Casella, S.; Casella, E.; Crippa, M.; et al. Post-SARS-CoV-2 Acute Telogen Effluvium: An Expected Complication. J. Clin. Med. 2022, 11, 1234. https://doi.org/10.3390/jcm11051234
Monari P, Gualdi G, Bettoni G, Costa R, Ragni G, Zani F, Bianchi G, Casella S, Casella E, Crippa M, et al. Post-SARS-CoV-2 Acute Telogen Effluvium: An Expected Complication. Journal of Clinical Medicine. 2022; 11(5):1234. https://doi.org/10.3390/jcm11051234
Chicago/Turabian StyleMonari, Paola, Giulio Gualdi, Giorgio Bettoni, Raffaella Costa, Giorgio Ragni, Francesca Zani, Giovanna Bianchi, Silvia Casella, Elisa Casella, Massimo Crippa, and et al. 2022. "Post-SARS-CoV-2 Acute Telogen Effluvium: An Expected Complication" Journal of Clinical Medicine 11, no. 5: 1234. https://doi.org/10.3390/jcm11051234